Next-Generation Antibody Therapies – Your 2016 Guide to Trends, R&D and Predicted Revenues Where are next-generation antibody therapies heading? Visiongain’s new report shows you potential revenues to 2026, giving R&D trends, opportunities and sales forecasting.
Discover in our study the most promising and lucrative parts of that industry. Our analysis lets you assess forecasted sales at overall world market, submarket, product and regional level. That work shows you results, interviews, trends and opportunities.
Many opportunities remain in that expanding market for new biological drugs. Discover what its future holds, with the following sections explaining how our study can help your work.
Forecasts from 2016-2026 and other analyses show you revenue potentials Besides revenue forecasting to 2026, our new study shows you recent results, growth rates, and market shares. There you find original analyses exploring developments and business outlooks.
In our report you get 87 tables and 46 charts explaining that market. See what its future holds and the potential gains. Find data to benefit your plans, decisions and proposals.
There you also discover qualitative analyses (including SWOT and STEP analysis), product profiles and commercial developments. You also find our interviews with three companies – Ablynx, arGEN-X and Mersana Therapeutics – giving insight to help you stay ahead.
Sales predictions for the world market and submarkets – see what is possible Along with revenue prediction for the overall world market, our study shows you revenue forecasts to 2026 for the following five submarkets: • Antibody-drug conjugates (ADCs) • Engineered antibodies • Bispecific antibodies • Antibody fragments and antibody-like proteins (ALPs) • Biosimilar antibody therapies.
That investigation discusses what stimulates and restrains business. There discover what is possible for monoclonal antibodies and other agents. You find dynamics of the industry and assess its sales potentials, exploring treatments giving high commercial opportunities.
Leading next-generation therapeutic antibodies – what are their prospects? How will leading next-generation antibody therapies perform to 2026 at world level? Our study forecasts individual revenues of seven products, showing you what revenues are possible: • Adcetris • Kadcyla • Gazyva/Gazyvaro • Poteligeo • Removab • Blincyto • Kalbitor.
Discover how high those sales can go. With our study you see what is happening, exploring trends, challenges and opportunities.
Our analysis also breaks its main world forecast into geographical submarkets.
Leading regions – assess prospects for next-generation antibody sales In addition to analyses of the overall world market, our study lets you explore individual revenue forecasts to 2026 for four regional markets: • US • EU5 group • Asia-Pacific region • Latin America • Rest of the World.
With that analysis you see where the highest and fastest expanding revenues can occur. That industry holds great potential for opportunities and rising sales. Discover what is possible.
Potential for market growth – how much expansion possible by 2020? Our study predicts high revenue growth from 2016 to 2026. Launches of novel therapies, investments from international pharmaceutical companies and increasing demand for treatments for serious chronic diseases will increase those agents’ sales from 2016 to 2026.
Our analysis forecasts that the worldwide next-generation antibodies market will generate $11.6 billion in 2020. There discover capabilities, progress, and commercial prospects, helping you stay ahead in knowledge and benefit your reputation for commercial insight.
Research and development – assess innovation, trends and possibilities What about R&D – the pipeline for new drugs? Our report explains, covering these fields: • Antibody-drug conjugates (ADCs) • Engineered antibodies • Bispecific antibodies • Antibody fragments and antibody-like proteins (ALPs) • Other progress in next-generation antibody development.
Our study also discusses these agents and technologies, among others: • Site-specific linkers • Glycosylation or glycoengineering • Defucosylation • Amino acid modification • Enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) • Bispecific, trispecific and multi-specific antibodies • Domain fragments • Single-chain variable fragments • Alternative scaffolds: DARPins, anticalins, Affibodies, Fynomers, Affilins, Adnectins and i-bodies • Combination therapies.
R&D is particularly strong for antibody-drug conjugates. Also novel products and biobetters with high safety, efficacy and affordability are in great demand. Our work explains, discussing many issues to help your work.
Issues affecting the next-generation antibody therapies industry from 2016 Our survey discusses forces affecting those companies. There you find discussions of these and other issues: • Approved products indicating a path to regulatory and market acceptance • R&D for next generation antibodies – explore technologies and potentials • Challenges with current monoclonal antibody (mAb) therapies • Big pharma companies investing in next-generation antibody research and development • Biosimilars and their effects on the market for those next-generation biologics.
That investigation explains social, technological, economic and political forces, with emphasis on competition and business outlooks. Assess what drives and restrains developers, producers and marketers of those emerging biologic medicines.
7 ways Next-Generation Antibody Therapies Market Forecast 2016-2026 helps you In these seven main ways, our new report helps your research, analysis, plans, decisions and presentations: • Revenue forecasts to 2026 for the world next-generation antibody therapies market and 5 segments – discover that industry’s prospects, seeing its sales potentials • Predicted revenues to 2026 for the leading 4 regional markets – assess sales outlooks in the US, EU5, Asia-Pacific and Latin America • Sales potentials of 7 leading drugs to 2026 – see how high products’ revenues can go • Review of R&D – investigate trends and progress, seeing what is possible, finding the most promising developments • Discussion of what stimulates and restrains leading companies – explore strengths, weaknesses, opportunities and threats, assessing that industry’s prospects • Outlooks for established competitors and new market entrants – hear what scope exists for companies to increase their business and compete from 2016 • Interviews from our survey, showing views from 3 companies – gain insight from that industry to help your work.
There you gain competitive intelligence found only in our analysis, finding sales potentials. Benefit your influence by exploring commercial progress, opportunities and potentials.
Trying our new study now lets you discover antibody trends, opportunities and forecasts With our new report, by Visiongain’s UK-based in-house analysts, you discover analysis to help you stay ahead in knowledge. See there what the future holds for developers, producers and sellers of therapeutic antibodies. Find data you get nowhere else.
Our investigation is for everyone analysing biopharmaceuticals. There you discover data and forecasts for new antibody-based drugs. Avoid missing out and falling behind in knowledge. Instead please get our new report here now.
Visiongain is a trading partner with the US Federal Government CCR Ref number: KD4R6
1. Report Overview
1.1 Next-Generation Antibody Therapies Overview
1.2 Global Next-Generation Antibody Therapies Market Segmentation
1.3 Why you Should Read this Report
1.4 How this Report Delivers
1.5 Main Questions Answered by This Analytical Study
1.6 Who is This Report For?
1.7 Methodology
1.8 Frequently Asked Questions (FAQ)
1.9 Associated Reports
1.10 About Visiongain
2. Introduction to Next-Generation Antibody Therapies
2.1 Antibodies: An Overview
2.1.1 Monoclonal versus Polyclonal Antibodies
2.1.2 A Brief History of Antibody Drug Development
2.1.3 The Antibody Manufacturing Process
2.1.4 Trends in Antibody Development
2.2 Defining Next-Generation Antibodies
2.3 Classification of Next-Generation Antibody Therapies
2.4 The Need for Next-Generation Technologies
2.5 Development Trends for Next-Generation Antibodies
2.6 Scope of this Report
2.7 Phases of Clinical Trials
3. Next-Generation Antibody Therapies: World Market 2016-2026
3.1 The World Next-Generation Antibody Therapies Market Overview and Segmentation, 2015
3.2 Leading Next-Generation Antibody Therapies
3.3 World Next-Generation Antibody Therapies Market: Sales Forecast 2016-2026
3.4 How Will Segmental Market Shares Change to 2026?
3.4 World Next-Generation Antibody Therapies Market: Drivers and Restraints 2016-2026
4. Leading Regional Markets 2016-2026
4.1 Regional Breakdown of the World Next-Generation Antibody Therapies Market, 2015
4.2 World Next-Generation Antibody Therapies Market: Regional Forecast 2016-2026
4.3 How Will Regional Market Shares Change to 2026?
4.4 US Next-Generation Antibody Therapies Market 2015-2026
Visiongain’s reports are based on comprehensive primary and secondary research. Those studies provide global market forecasts (sales by drug and class, with sub-markets and leading nations covered) and analyses of market drivers and restraints (including SWOT analysis) and current pipeline developments. To find out more about our reports methodology, please email sara.peerun@visiongain.com
Win a Free Visiongain Pharma report – ‘Like’ our Pharma Facebook page with the link below and enter into our raffle to win a free, unlocked Visiongain report, choosing your relevant report from our reports selection.
Visiongain Publishes Checkpoint Inhibitors for Treating Cancer Market Report 2021-2031
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
Visiongain Publishes Drug Delivery Technologies Market Report 2021-2031
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.
Visiongain Pharma
Visiongain Pharma
Visiongain Pharma
